torvacard 20 mg õhukese polümeerikattega tablett
zentiva k.s. - atorvastatiin - õhukese polümeerikattega tablett - 20mg 90tk; 20mg 30tk
torvacard 10 mg õhukese polümeerikattega tablett
zentiva k.s. - atorvastatiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 30tk
kisplyx
eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
lenvima
eisai gmbh - lenvatinibmesülaat - kilpnäärme kasvajad - antineoplastilised ained - lenvima on näidustatud monotherapy raviks täiskasvanud patsientidel, kellel on progresseeruv, lokaalselt kaugelearenenud või metastaatilise, liigendatud (papillary/follikulaarne/hürthle cell) kilpnäärme kartsinoom (dtc), rasksulavad, et radioaktiivse joodi (rai). lenvima on näidustatud monotherapy raviks täiskasvanud patsientidel, kaugelearenenud või unresectable hepatotsellulaarne kartsinoom (hcc), kes on saanud ilma eelneva süsteemse ravi.
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
jylamvo
therakind (europe) limited - metotreksaadi - arthritis, psoriatic; precursor cell lymphoblastic leukemia-lymphoma; psoriasis; arthritis, rheumatoid; arthritis - antineoplastilised ained - selles rheumatological ja nahahaiguste diseasesactive reumatoidartriidiga täiskasvanud patsientidel. polyarthritic vormid, aktiivne, tõsine juveniilne idiopaatiline artriit (jia) noorukitel ja lastel vanuses 3 aastat ja rohkem, kui vastuseks mitte-steroidsete põletikuvastaste ravimite (mspva) on olnud ebapiisav. tõsiseid, ravi-tulekindlad -, blokeerimis-psoriaas, mis ei allu piisavalt muud liiki ravile, nt valgusravi, psoralen ja ultraviolett kiirguse (puva) ravi ja retinoidide, ja raske psoriaatiline artriit täiskasvanud patsientidel. selles oncologymaintenance ravi ägeda lümfoblastilise leukeemia (all) täiskasvanutel, noorukitel ja lastel vanuses 3 aastat ja rohkem.
pantoprazole-mepha gastroresistentne tablett
teva b.v. - pantoprasool - gastroresistentne tablett - 20mg 56tk
pantoprazole-mepha gastroresistentne tablett
teva b.v. - pantoprasool - gastroresistentne tablett - 40mg 56tk; 40mg 100tk; 40mg 14tk; 40mg 28tk
oxaliplatin kabi 5mg/ml infusioonilahuse kontsentraat
fresenius kabi polska sp. z o.o. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 10ml 1tk
lormed 7,5 mg tablett
pro.med.cs praha a.s. - meloksikaam - tablett - 7,5mg 300tk